
11 Jan 2019 Research
Lymphoma: Understanding relapse and treatment resistance
What is this research looking at?
Our immune system is remarkable. It is made up of many different types of immune cells that work together to protect the body from infection by pathogens such as bacteria, viruses and parasites.
We are investigating what happens when a certain type of cell in the immune system, known as B cells, starts growing out of control and develops into blood cancers such as leukaemia, lymphoma and myeloma.
We want to know what happens when B cells mature normally from precursor cells in the bone marrow and discover what has gone wrong when they turn into cancer cells instead.
Considerable success has been achieved in the treatment of lymphoma. However, a significant unmet need remains: roughly 40% of patients either do not respond to treatment or the condition recurs after treatment. Currently, our ability to predict which patients will fail treatment is poor.
By taking a detailed look at B cells as they develop and specialise, we can spot small groups of dangerous cells that are particularly likely to turn into cancer and identify the genetic faults that drive B cells to grow out of control.
We are using our knowledge to create new models for the development of B cells and blood cancers in the lab, so we can find new ways to treat or even prevent these deadly diseases.
Our research uses a model of lymphoma to test the response to treatments and development of resistance. A main advantage of the model is that we can interrogate these questions on a well-defined scenario and can perform iterative tests and predictions. Further, the model generated in this project will allow initial testing of novel treatments.
What could this mean for people with leukaemia?
This research could inform the medical decision of when to use combination and novel therapies for patients with a higher probability of developing resistance to standard treatment, alongside bringing safer treatments to patients.
Official project title: Development of a model system to study diffuse large B cell lymphoma clonal evolution
Related posts
12 June 2021
First Medical Research Council and Leukaemia UK Clinical Research Training Fellow shares project highlights
Dr Sandeep Potluri’s findings will contribute towards a better understanding, cure and treatments of leukaemia and blood cancers
19 August 2022
Leukaemia Care and Leukaemia UK announce financial support collaboration
Leukaemia Care and Leukaemia UK are pleased to announce a collaboration to provide financial support to people affected by leukaemia, through the financial hardship fund. Leukaemia Care have provided 364…
27 September 2024
Leukaemia UK calls upon government to increase blood testing capacity
Together with Leukaemia Care, we’re calling on the new Secretary of State for Health and Social Care to focus on ‘business as usual’ primary care testing alongside innovation, amid concerns…
13 November 2023
This year’s Olive Boles Innovation Award winner announced
Dr Kevin Rattigan, University of Glasgow, has been selected as this year’s Olive Boles Innovation Award winner – an accolade given to one Leukaemia UK John Goldman Fellow each year….